Ozempic has become a phenomenon, generating nearly $14 billion in sales in 2023 for Novo Nordisk, showcasing a massive demand primarily driven by its weight-loss benefits despite being intended for diabetes treatment.
Novo Nordisk's rise to pharmaceutical dominance is plagued by multiple regulatory issues, including a significant $59 million fine for lack of FDA disclosures and ongoing investigations into predatory pricing practices.
Despite facing regulatory headwinds, investors are focused on the potential long-term stock performance of Novo Nordisk, emphasizing that future projections can be incredibly difficult to ascertain with certainty.
The dual-purpose nature of Ozempic and Wegovy has turned them into incredibly lucrative products, with weight-loss being an unintended yet major driver of its market success, raising ethical questions.
Collection
[
|
...
]